阿托伐他汀钙联合银杏酮酯滴丸对脑梗死患者颈动脉斑块及粘附因子的影响  

Effects of the Combination Therapy of Atorvastatin with Ginkgo Biloba Extract Dripping Pill on Carotid Plaque in Patients with Cerebral Infarction and Serum Soluble Cell Adhesion Molecules

作　　者：李兰凤 付博 牛忠江 张雪凤 LI Lanfeng;FU Bo;NIU Zhongjiang(Department of Neurology,Harbin 242 Hospital,Harbin 150066,China)

机构地区：[1]哈尔滨二四二医院神经内科,哈尔滨150066

出　　处：《航空航天医学杂志》2020年第4期387-390,共4页Journal of Aerospace medicine

摘　　要：目的探究阿托伐他汀钙联合银杏酮酯滴丸对脑梗死患者颈动脉斑块及粘附因子的影响。方法对2013年2月-2015年2月发病时间均为72 h以内的168例急性动脉粥样硬化性脑梗死住院患者为实验对象,按照住院号码,以随机抽样的方式分为两组,各84人。实验组给予口服银杏酮酯滴丸+阿托伐他汀钙进行治疗,对照组给予阿托伐他汀钙治疗,对两组患者治疗前后颈动脉斑块、内膜-中膜厚度以及可溶性细胞粘附分子进行比较分析。结果两组患者治疗前血清可溶性细胞间黏附分子-1(sICAM-1)、可溶性血管细胞黏附分子-1(sVCAM-1)间差别比较没有显著差别(P>0.05);经治疗后两组患者sICAM-1及sVCAM-1检测结果与治疗前相对比显著下降(P<0.05);实验组在经12周的治疗以及出院后继续服药12周后sICAM-1及sVCAM-1降低的比对照组同期更明显(P<0.05)。经12周的治疗以及出院后继续服药12周两组颈动脉斑块数量、斑块面积以及IMT值均较治疗前好转(P<0.05)。实验组经12周的治疗以及出院后继续服药12周后在颈动脉斑块数量、斑块面积以及IMT值方面较对照组减少的更明显(P<0.05)。两组在经治疗后NIHSS评分和BI评分均较治疗前好(P<0.05);实验组经12周的治疗以及出院后继续服药12周后NIHSS评分及BI评分变化均较对照组同期好(P<0.05)。两组不良反应情况比较则没有明显不同(P>0.05)。结论阿托伐他汀钙与银杏酮酯滴丸联合使用可以显著降低脑梗死颈动脉粥样硬化患者血清可溶性粘附分子的表达,具有强大的抗氧化、逆转及稳定斑块的作用。Objective To investigate the effects of the combination therapy of atorvastatin with ginkgo biloba extract dripping pill on carotid plaque in patients with cerebral infarction and serum soluble cell adhesion molecules.Methods In February 2013 to February 2015 in January 168 cases from Fengxian District central hospital within 72 hours of the acute cerebral infarction patients admitted to the hospital as the research object,according to patients were randomly divided into 2 groups,each group of 84 people.The treatment group received atorvastatin calcium combined with Ginkgo biloba extract dripping pill orally,the control group with atorvastatin calcium treatment,the serum levels of sICAM-1 and sVCAM-1 and carotid IMT were measured before and after the two groups of patients treatment,changes in the number of plaque area and plaque.Results The two group received no treatment for sICAM-1 and sVCAM-1 were no significant difference(P>0.05);In the treatment of 12 W and 12 W in two groups were sICAM-1 and sVCAM-1 decreased significantly than before treatment(P<0.05);In the treatment of 12 W and 12 W in treatment group sICAM-1 and sVCAM-1 were lower than that of the control group over the same period the better(P<0.05).The two groups before treatment IMT value,there was no significant difference in the number of plaque area and plaque(P>0.05);In the treatment of 12 W and 12 W in two groups were IMT value,the amount of plaque area and plaque reduction ratio did not receive treatment improved significantly(P<0.05);In the treatment of 12 W and 12 W in treatment group was IMT,the number of plaque area and plaque reduction ratio compared with the control group,the better(P<0.05).NIHSS and BI score before treatment in two groups were not significantly different(P>0.05);In the treatment of 12 W and 12 W were two groups of NIHSS score and BI score changes were compared with those before treatment(P<0.05);In the treatment of 12 W and NIHSS score and BI score changes in 12 W treatment group than the control group at the same time

关 键 词：脑梗死 稳定斑块 可溶性细胞粘附分子 银杏酮酯 

分 类 号：R743[医药卫生—神经病学与精神病学]